stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Revenue growth
Novo Nordisk A/S's revenue growth over the twelve months to 30 June 2026 was 13.2%, up 2.0 percentage points from fiscal 2025 (11.1%). Over the past ten years it has ranged from 0.78% (fiscal 2018) to 34.6% (fiscal 2023); the current reading is higher than 64% of that period. That is above the Drug Manufacturers General industry median of 6.72% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 11.1% | (13.74) |
| FY2024 | 24.9% | (9.73) |
| FY2023 | 34.6% | 22.74 |
| FY2022 | 11.9% | (3.33) |
| FY2021 | 15.2% | 8.85 |
| FY2020 | 6.33% | (0.64) |
| FY2019 | 6.97% | 6.19 |
| FY2018 | 0.78% | (1.36) |
| FY2017 | 2.14% | (1.29) |
| FY2016 | 3.43% | 2.01 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 4.47% | (33.14) |
| Mar 2026 | 37.6% | 36.94 |
| Dec 2025 | 0.67% | (11.03) |
| Sep 2025 | 11.7% | (7.33) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S | 13.2% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GSK GSK PLC Sponsored ADR compare | 6.90% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement